Ferric Pyrophosphate
drugOn this page
Also known as Iron (as pyrophosphate)Iron(iii) pyrophosphate
Summary
Ferric Pyrophosphate (CHEMBL4297752) is a phase-3 clinical-stage unknown; indicated across 2 conditions including anemia and helicobacter pylori infectious disease.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 2 conditions
- Clinical trials: 5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297752 |
| Name | Ferric Pyrophosphate |
| Type | Unknown |
| Max phase | 3 |
Also known as: Ferric pyrophosphate, Iron (as pyrophosphate), Iron(iii) pyrophosphate, FERRIC PYROPHOSPHATE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| anemia | 3 | MONDO:0002280 | EFO:0004272 |
| Helicobacter pylori infectious disease | 1 | MONDO:0006781 | EFO:1000961 |
Clinical trials
Total trials: 5.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 4 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00867867 | PHASE1 | COMPLETED | Ferrous Fumarate and Ferric Pyrophosphate as Food Fortificants in Developing Countries |
| NCT02255942 | Not specified | COMPLETED | The Effect of Zinc on Iron Bioavailability From Fortified Extruded Rice Fortified With Ferric Pyrophosphate |
| NCT02714075 | Not specified | COMPLETED | Comparison of Iron Absorption From Extruded FePP-fortified Rice Containing Zinc, Citric Acid/Trisodium Citrate and EDTA |
| NCT03586245 | Not specified | COMPLETED | Iron Absorption From Iron Enriched Aspergillus Oryzae in Females Using Stable Isotope Methodology |
| NCT03762148 | Not specified | COMPLETED | Determination of a Dose-dependent Effect of GOS on Iron Absorption, and Addition of Vitamin C |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: anemia